Your Cart is Empty
The LDN Book 3
The LDN Book, Volume 3 is both a resource for practitioners, pharmacists and patients and a renewed call for further research on the healing potential of this generic drug.
Find an LDN Book Stockist, stocking LDN Book 3
Who Wrote What in the Book?
Preface by Linda Elsegood, Founder LDN Research Trust
Foreword by Pamela W. Smith, M.D., MPH, MS
Pharmacology and Best Clinical Practices by J. Stephen Dickson, BSC (hons) MRPharmS
Drug-Resistant Depression by Dr. Elizabeth Livengood, NMD
Virally Damaged Tissues ( including: COVID-19, Herpes Simplex (HSV 1 & 2), Varicella-Zoster, Human Parvovirus B19 (B19V), Epstein-Barr (EBV) by Sarah J. Zielsdorf, MD, MS
LDN and Longevity by Yusuf M. (JP) Saleeby, MD
Mixed Connective Tissue Disease by Deanna Windham, DO
Mold Illness and CIRS by Kent Holtorf, MD
Ophthalmic Conditions by Sebastian Denison, RPh, FAAR
Long COVID by Professor Angus G. Dalgleish, FRCP FRCPath FMedSci and Wai M. Liu, PhD
Cancer and Case Studies by Angus Dalgleish,FRCP FRCPath FMedSc Wai M. Liu, PhD and Nasha Winters, ND, FABNO
Epilogue by Yoon Hang “John” Kim, MD
APPENDIX - Dosing Protocols by Sarah J. Zielsdorf, MD, MS
€26,95
The LDN Book, Volume 3 is a comprehensive resource for practitioners, pharmacists, and patients, exploring the clinical applications and research surrounding Low Dose Naltrexone (LDN).
This volume features contributions from leading clinicians and researchers, covering topics including pharmacology, clinical practices, drug-resistant depression, viral conditions, longevity, connective tissue disorders, ophthalmic conditions, long COVID, cancer, and dosing protocols.
Contributors include Linda Elsegood, Pamela W. Smith, J. Stephen Dickinson, Dr. Elizabeth Livengood, Sarah J. Zielsdorf, Yusuf M. Saleeby, Deanna Windham, Kent Holtorf, Sebastian Denison, Professor Angus G. Dalgleish, Wai M. Liu, Nasha Winters, and others.